Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.73 |
| ▸ | SRC | P12931 | 14/20 | 0.73 |
| ▸ | ABL1 | P00519 | 13/20 | 0.73 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.73 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.73 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.73 |
| ▸ | PRKDC | P78527 | 12/20 | 0.73 |
| ▸ | HCK | P08631 | 12/20 | 0.73 |
| ▸ | EGFR | P00533 | 11/20 | 0.73 |
| ▸ | MTOR | P42345 | 11/20 | 0.73 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.73 |
| ▸ | RET | P07949 | 6/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28455902 | 0.91 | SRC (0.76) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL24467463 | 0.86 | KDR (0.70) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL29904440 | 0.86 | KDR (0.81) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL20534730 | 0.86 | KDR (0.81) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL2320180 | 0.84 | SRC (1.00) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL20535281 | 0.83 | KDR (1.00) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL2315798 | 0.82 | SRC (1.00) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL29391405 | 0.81 | SRC (1.00) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL14574867 | 0.81 | SRC (1.00) | KDRSRCABL1PIK3CDPIK3CA | |
| SCHEMBL3610512 | 0.81 | SRC (1.00) | KDRSRCABL1PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026049-A1 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026049-A1 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | CD74, HAVCR2, FCGR2A | KDR 220/4885SRC 125/4885ABL1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.